Barbara Hero

15.2k total citations · 1 hit paper
170 papers, 8.3k citations indexed

About

Barbara Hero is a scholar working on Neurology, Molecular Biology and Cancer Research. According to data from OpenAlex, Barbara Hero has authored 170 papers receiving a total of 8.3k indexed citations (citations by other indexed papers that have themselves been cited), including 147 papers in Neurology, 63 papers in Molecular Biology and 57 papers in Cancer Research. Recurrent topics in Barbara Hero's work include Neuroblastoma Research and Treatments (143 papers), Cancer, Hypoxia, and Metabolism (55 papers) and Cancer therapeutics and mechanisms (38 papers). Barbara Hero is often cited by papers focused on Neuroblastoma Research and Treatments (143 papers), Cancer, Hypoxia, and Metabolism (55 papers) and Cancer therapeutics and mechanisms (38 papers). Barbara Hero collaborates with scholars based in Germany, United States and United Kingdom. Barbara Hero's co-authors include Frank Berthold, Thorsten Simon, Matthias Fischer, Frank Westermann, Andreas Faldum, Katherine K. Matthay, Andrew D.J. Pearson, Susan L. Cohn, Wendy B. London and Tom Monclair and has published in prestigious journals such as New England Journal of Medicine, Nature Genetics and Journal of Clinical Oncology.

In The Last Decade

Barbara Hero

164 papers receiving 8.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report

2008 1.3k citations Garrett M. Brodeur, Barbara Hero et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Barbara Hero Germany	48	6.3k	3.7k	2.5k	1.6k	1.4k	170	8.3k
Judith G. Villablanca United States	38	4.9k 0.8×	3.2k 0.9×	1.8k 0.7×	1.5k 1.0×	821 0.6×	72	6.8k
Victoria Castel Spain	31	5.1k 0.8×	2.7k 0.7×	2.1k 0.8×	1.2k 0.8×	841 0.6×	155	6.1k
Robert B. Gerbing United States	51	5.3k 0.8×	4.6k 1.2×	2.1k 0.8×	2.1k 1.4×	826 0.6×	239	11.0k
Bruno De Bernardi Italy	43	5.1k 0.8×	2.6k 0.7×	1.7k 0.7×	996 0.6×	1.2k 0.9×	163	6.8k
Dominique Valteau‐Couanet France	46	3.7k 0.6×	2.5k 0.7×	1.7k 0.7×	1.4k 0.9×	717 0.5×	189	6.6k
Julie R. Park United States	46	4.9k 0.8×	3.3k 0.9×	2.1k 0.8×	3.6k 2.3×	638 0.5×	185	8.5k
Véronique Mosseri France	47	2.5k 0.4×	1.9k 0.5×	2.4k 1.0×	2.7k 1.8×	1.4k 1.0×	122	7.4k
Birgit Geoerger France	43	1.8k 0.3×	2.6k 0.7×	1.1k 0.4×	2.0k 1.3×	462 0.3×	209	6.2k
Ronald R. de Krijger Netherlands	51	1.3k 0.2×	2.3k 0.6×	3.2k 1.3×	1.0k 0.7×	5.6k 4.1×	297	9.9k
Penelope Brock United Kingdom	34	1.2k 0.2×	1.4k 0.4×	775 0.3×	1.6k 1.1×	1.1k 0.8×	93	4.9k

Countries citing papers authored by Barbara Hero

Since Specialization

Citations

This map shows the geographic impact of Barbara Hero's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara Hero with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara Hero more than expected).

Fields of papers citing papers by Barbara Hero

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara Hero. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara Hero. The network helps show where Barbara Hero may publish in the future.

Co-authorship network of co-authors of Barbara Hero

This figure shows the co-authorship network connecting the top 25 collaborators of Barbara Hero. A scholar is included among the top collaborators of Barbara Hero based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barbara Hero. Barbara Hero is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jiménez-Pastor, Ana, Glen J. Weiss, L. Cerdá Alberich, et al.. (2025). Risk stratification in neuroblastoma patients through machine learning in the multicenter PRIMAGE cohort. Frontiers in Oncology. 15. 1528836–1528836. 1 indexed citations

Jiménez-Pastor, Ana, Glen J. Weiss, Leonor Cerdá-Alberich, et al.. (2024). Overall survival prediction and risk stratification in patients with neuroblastoma through machine learning in the large multi-institutional PRIMAGE cohort.. Journal of Clinical Oncology. 42(16_suppl). 10054–10054.

Krug, B., Jörg Fuchs, Steven W. Warmann, et al.. (2023). Image‐defined risk factors in localized thoracic neuroblastoma and ganglioneuroma. Pediatric Blood & Cancer. 70(10). e30605–e30605. 2 indexed citations

Ebinger, Martin, Ruth Ladenstein, Thorsten Simon, et al.. (2023). Multimodal Therapy with Consolidating Haploidentical Stem Cell Transplantation and Dinutuximab Beta for Patients with High-Risk Neuroblastoma and Central Nervous System Relapse. Journal of Clinical Medicine. 12(19). 6196–6196. 4 indexed citations

Rossor, Thomas, E. Ann Yeh, Yasmin Khakoo, et al.. (2022). Diagnosis and Management of Opsoclonus-Myoclonus-Ataxia Syndrome in Children. Neurology Neuroimmunology & Neuroinflammation. 9(3). 31 indexed citations

Berthold, Frank, Angela Ernst, Sandra Ackermann, et al.. (2021). Genetic Alterations and Resectability Predict Outcome in Patients with Neuroblastoma Assigned to High-Risk Solely by MYCN Amplification. Cancers. 13(17). 4360–4360. 2 indexed citations

Chung, Christine H., Tom Boterberg, John T. Lucas, et al.. (2021). Neuroblastoma. Pediatric Blood & Cancer. 68(S2). e28473–e28473. 88 indexed citations

Berthold, Frank, et al.. (2021). Hypercalcemia is a frequent side effect of 13‐cis‐retinoic acid treatment in patients with high‐risk neuroblastoma. Pediatric Blood & Cancer. 69(2). e29374–e29374. 4 indexed citations

Berthold, Frank, Claudia Spix, R. Erttmann, et al.. (2021). Neuroblastoma Screening at 1 Year of Age: The Final Results of a Controlled Trial. JNCI Cancer Spectrum. 5(4). 6 indexed citations

10.

Berthold, Frank, Carolina Rosswog, Holger Christiansen, et al.. (2021). Clinical and molecular characterization of patients with stage 4(M) neuroblastoma aged less than 18 months without MYCN amplification. Pediatric Blood & Cancer. 68(8). e29038–e29038. 4 indexed citations

11.

Zolk, Oliver, Norbert Graf, Thorsten Simon, et al.. (2021). Cardiovascular Health Status And Genetic Risk In Survivors of Childhood Neuroblastoma and Nephroblastoma Treated With Doxorubicin: Protocol of the Pharmacogenetic Part of the LESS-Anthra Cross-Sectional Cohort Study. JMIR Research Protocols. 11(2). e27898–e27898. 3 indexed citations

12.

Peitzsch, Mirko, Elizabeth R. Butch, Anastasios Mangelis, et al.. (2019). Biochemical testing for neuroblastoma using plasma free 3‐O‐methyldopa, 3‐methoxytyramine, and normetanephrine. Pediatric Blood & Cancer. 67(2). e28081–e28081. 16 indexed citations

13.

Fischer, Matthias, Thomas F.E. Barth, Wolfgang Mueller‐Klieser, et al.. (2018). LDHA in Neuroblastoma Is Associated with Poor Outcome and Its Depletion Decreases Neuroblastoma Growth Independent of Aerobic Glycolysis. Clinical Cancer Research. 24(22). 5772–5783. 54 indexed citations

14.

Simon, Thorsten, Beate Häberle, Barbara Hero, Dietrich von Schweinitz, & Frank Berthold. (2013). Role of Surgery in the Treatment of Patients With Stage 4 Neuroblastoma Age 18 Months or Older at Diagnosis. Journal of Clinical Oncology. 31(6). 752–758. 84 indexed citations

15.

García, Idoia, José Ríos, Gema Doménech, et al.. (2012). A Three-Gene Expression Signature Model for Risk Stratification of Patients with Neuroblastoma. Clinical Cancer Research. 18(7). 2012–2023. 51 indexed citations

16.

Schulte, Johannes H., Hagen S. Bachmann, Katleen De Preter, et al.. (2011). High ALK Receptor Tyrosine Kinase Expression Supersedes ALK Mutation as a Determining Factor of an Unfavorable Phenotype in Primary Neuroblastoma. Clinical Cancer Research. 17(15). 5082–5092. 72 indexed citations

17.

Oberthuer, André, Lars Kaderali, Yvonne Kahlert, et al.. (2008). Subclassification and Individual Survival Time Prediction from Gene Expression Data of Neuroblastoma Patients by Using CASPAR. Clinical Cancer Research. 14(20). 6590–6601. 19 indexed citations

18.

Oehme, Ina, Hedwig E. Deubzer, Dennis Wegener, et al.. (2008). Histone Deacetylase 8 in Neuroblastoma Tumorigenesis. Clinical Cancer Research. 15(1). 91–99. 320 indexed citations

19.

Fulda, Simone, Christopher Poremba, Bernd Berwanger, et al.. (2006). Loss of Caspase-8 Expression Does Not Correlate with MYCN Amplification, Aggressive Disease, or Prognosis in Neuroblastoma. Cancer Research. 66(20). 10016–10023. 33 indexed citations

20.

Fischer, Matthias, André Oberthuer, Benedikt Brors, et al.. (2006). Differential Expression of Neuronal Genes Defines Subtypes of Disseminated Neuroblastoma with Favorable and Unfavorable Outcome. Clinical Cancer Research. 12(17). 5118–5128. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact